全文获取类型
收费全文 | 1871544篇 |
免费 | 144129篇 |
国内免费 | 14629篇 |
学科分类
医药卫生 | 2030302篇 |
出版年
2021年 | 20582篇 |
2020年 | 14587篇 |
2019年 | 19027篇 |
2018年 | 25818篇 |
2017年 | 20999篇 |
2016年 | 21807篇 |
2015年 | 27007篇 |
2014年 | 36539篇 |
2013年 | 48735篇 |
2012年 | 68324篇 |
2011年 | 71941篇 |
2010年 | 44824篇 |
2009年 | 40723篇 |
2008年 | 63489篇 |
2007年 | 66534篇 |
2006年 | 66410篇 |
2005年 | 62375篇 |
2004年 | 58106篇 |
2003年 | 54843篇 |
2002年 | 51792篇 |
2001年 | 95606篇 |
2000年 | 96861篇 |
1999年 | 79862篇 |
1998年 | 21386篇 |
1997年 | 18848篇 |
1996年 | 17663篇 |
1995年 | 17820篇 |
1994年 | 16324篇 |
1993年 | 14632篇 |
1992年 | 58029篇 |
1991年 | 55888篇 |
1990年 | 53521篇 |
1989年 | 51190篇 |
1988年 | 46537篇 |
1987年 | 45262篇 |
1986年 | 42474篇 |
1985年 | 40188篇 |
1984年 | 29436篇 |
1983年 | 24960篇 |
1982年 | 13912篇 |
1979年 | 25545篇 |
1978年 | 17586篇 |
1977年 | 14893篇 |
1976年 | 13866篇 |
1975年 | 14540篇 |
1974年 | 17653篇 |
1973年 | 16947篇 |
1972年 | 15713篇 |
1971年 | 14461篇 |
1970年 | 13440篇 |
排序方式: 共有10000条查询结果,搜索用时 421 毫秒
1.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
2.
Kienbaum Peter Schaefer Maximilian S. Weibel Stephanie Schlesinger Tobias Meybohm Patrick Eberhart Leopold H. Kranke Peter 《Der Anaesthesist》2022,71(2):123-128
Die Anaesthesiologie - Auch wenn für Anästhesiologen über Jahrzehnte die Prophylaxe und Therapie postoperativer Schmerzen im Rahmen des postoperativen Patientenkomforts an vorderster... 相似文献
3.
4.
5.
6.
7.
8.
目的分析盐酸利托君治疗晚期先兆流产保胎患者的临床疗效及不良反应发生率。方法选取2019年6—12月本院收治的行硫酸镁保胎治疗的35例晚期先兆流产患者作为对照组,另选取2020年1—7月本院收治的行盐酸利托君保胎治疗的35例晚期先兆流产患者作为研究组,比较两组治疗情况、保胎成功率、不良反应发生率、新生儿Apgar评分。结果研究组宫缩消失时间、止血时间、腹痛缓解时间、腰痛缓解时间、起效时间均短于对照组,且延长孕期时间长于对照组(P<0.05);研究组保胎成功33例(94.29%),对照组保胎成功26例(74.29%),差异有统计学意义(P<0.05);研究组不良反应发生率为22.86%,低于对照组的20.00%,但差异无统计学意义;研究组Apgar评分高于对照组,差异有统计学意义(P<0.05)。结论盐酸利托君治疗晚期先兆流产保胎患者,可尽快改善患者临床症状,有助于提高保胎成功率,改善母婴结局,且无明显不良症状,安全性较高,值得临床推广。 相似文献
9.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
10.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献